Abstract 4587: Identification of a monoclonal antibody to treat HCC xenografts with EGFRvIII expression

Abstract

Abstract Purposes:To identify monoclonal antibodies targeting Epidermal Growth Factor Receptor Variant III (EGFRvIII) and their anti-tumor effect on Hepatocellular carcinoma (HCC) with EGFRvIII expression. Procedures: Hybridoma technology was used to prepare monoclonal antibody recognizing EGFRvIII. Anti-tumor effects of several hybridoma clones were examined on HCC xenografts with EGFRvIII expression. Monoclonal antibody with highest growth-suppression effect on HCC was selected. Binding specificity of the antibody was tested by FACS assay. The targeting ability of this antibody was tested by injected the cyanin 5.5 labeled antibody into mice carrying EGFRvIII positive and negative xenografts. Findings: Among the tested monoclonal antibodies, mAb 12H23 has the highest tumor-suppression effect on HCC with EGFRvIII expression. mAb 12H23 bind preferentially to HCC cells with EGFRvIII expression. Cy5.5 labeled mAb 12H23 can significantly accumulate into EGFRvIII positive tumors but not the negative tumors. Conclusion: These data indicate mAb 12H23 is a potential biotherapeutic agent for treating HCC with EGFRvIII expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4587. doi:10.1158/1538-7445.AM2011-4587